Novavax
Stock Forecast, Prediction & Price Target
Novavax (NVAX) stock Price Target by analysts
$20.33
Potential upside: 114.65%
Novavax price prediction
What is Novavax stock analysts` prediction?
Novavax stock forecast: Based on 3 Wall Street analysts` predicted price targets for Novavax in the last 3 months, the avarage price target is $20.33, with a high forecast of $NaN. The average price target represents a 114.65% change from the last price of $9.47.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
Novavax stock Price Target by analysts
Full breakdown of analysts given Novavax price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
Mayank Mamtani B.Riley Financial | 0% 0/1 | 10 months ago | $22 132.25% upside | $7.58 | StreetInsider | Previous targets (0) |
Roger Song Jefferies | 0% 0/2 | 12 months ago | $25 163.92% upside | $10.15 | StreetInsider | Previous targets (1) |
Alec Stranahan Bank of America Securities | 0% 0/1 | 12 months ago | $14 47.79% upside | $10.45 | StreetInsider | Previous targets (0) |
Roger Song Jefferies | 0% 0/2 | about 1 year ago | $31 227.26% upside | $14.36 | TheFly | Previous targets (1) |
Vernon Bernardino H.C. Wainwright | 0% 0/1 | over 1 year ago | $19 100.58% upside | $9.94 | TheFly | Previous targets (0) |
Charles Duncan Cantor Fitzgerald | 0% 0/2 | over 3 years ago | $168 1673.55% upside | $40.62 | Pulse 2.0 | Previous targets (1) |
Charles Duncan Cantor Fitzgerald | 0% 0/2 | over 3 years ago | $174 1736.89% upside | $80.11 | Pulse 2.0 | Previous targets (1) |
Novavax Financial Estimates
Novavax Revenue Estimates
Novavax EBITDA Estimates
Novavax Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $1.14B N/A | $1.59B 39.48% | $983.70M -38.47% | Avg: $582.60M Low: $52.38M High: $1.26B avg. -40.77% | Avg: $532.43M Low: $304.50M High: $728.20M avg. -8.61% | Avg: $606.15M Low: $346.66M High: $829.02M avg. 13.84% | Avg: $719.1M Low: $411.26M High: $983.51M avg. 18.63% |
Net Income
% change YoY
| $-1.74B N/A | $-657.93M 62.26% | $-545.06M 17.15% | Avg: $-75.40M Low: $-219.58M High: $123.94M avg. 86.16% | Avg: $63.6M Low: $-149.13M High: $207.58M avg. 184.34% | Avg: $4.03M Low: $1.78M High: $5.95M avg. -93.66% | Avg: $46.85M Low: $20.78M High: $69.25M avg. 1062.5% |
EBITDA
% change YoY
| $-1.68B N/A | $-633.76M 62.42% | $-487.39M 23.09% | Avg: $-425.60M Low: $-923.49M High: $-38.27M avg. 12.67% | Avg: $-388.94M Low: $-531.96M High: $-222.44M avg. 8.61% | Avg: $-442.79M Low: $-605.61M High: $-253.24M avg. -13.84% | Avg: $-525.31M Low: $-718.46M High: $-300.43M avg. -18.63% |
EPS
% change YoY
| -$23.44 N/A | -$8.42 64.07% | -$5.41 35.74% | Avg: -$0.32 Low: -$2.18 High: $1.23 avg. 93.99% | Avg: $0.42 Low: -$1.48 High: $2.06 avg. 228.26% | Avg: $0.04 Low: $0.02 High: $0.06 avg. -90.40% | Avg: $0.47 Low: $0.21 High: $0.69 avg. 1062.50% |
Operating Expenses
% change YoY
| $2.83B N/A | $1.34B -52.66% | $779.12M -41.90% | Avg: $370.58M Low: $33.32M High: $804.10M avg. -52.43% | Avg: $338.66M Low: $193.68M High: $463.19M avg. -8.61% | Avg: $385.55M Low: $220.50M High: $527.32M avg. 13.84% | Avg: $457.40M Low: $261.59M High: $625.58M avg. 18.63% |
FAQ
What is Novavax stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 309.83% in 2025-2028.
We have gathered data from 6 analysts. Their low estimate is -219.58M, average is -75.40M and high is 123.94M.
What is Novavax stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of -4.22% in 2025-2028.
We have gathered data from 5 analysts. Their low revenue estimate is $52.38M, average is $582.60M and high is $1.26B.
What is Novavax stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 323.59% in 2025-2028.
We have gathered data from 6 analysts. Their low earnings per share estimate is -$2.18, average is -$0.32 and high is $1.23.
What is the best performing analyst?
In the last twelve months 3 analysts have been covering Novavax stock. The most successful analyst is Mayank Mamtani.